Zai Lab Adds Two Drugs to China's NRDL Reimbursement List
Zai Lab said five commercial medicines were included in China's 2026 NRDL, two of them for the first time. The list takes effect January 1, 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, citing Zai Lab's press release, five of the company's commercial medicines were included in China's 2026 National Reimbursement Drug List (NRDL). KarXT and VYVGART Hytrulo were listed for the first time, while three other products kept their coverage after renewal.
The updated list takes effect on January 1, 2027. The release provided no comparison with the prior period and did not quantify expected sales.
why it matters
For investors, the main point is market access: inclusion in the NRDL makes the drugs easier for patients in China to obtain with state reimbursement. The revenue impact has not been estimated, so the key signal will be sales trends after the list takes effect in 2027. The news is company-specific and does not change the picture for the broader market.
tags
instruments
sources
- Zai Lab Limited Adds 2 Drugs to China's NRDL — TradingView, 14 November 2026 at 05:38 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗